A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: The prognostic value of false-positive results

BJU International

Volumn 88, Issue 7, 2001, Pages 692-701

  Poulakis, V ^a,c   Witzsch, U ^a   De Vries, R ^a   Altmannsberger, H M ^a   Manyak, M J ^b   Becht, E ^a  

^a Acad Hosp of Johann W G U F   (Germany)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c Nordwest Hospital   (Germany)

Author keywords

Bladder cancer; BTAstat; Cystoscopy; NMP22; Tumour recurrence; Voided urinary cytology

Indexed keywords

MATRIX PROTEIN; NUCLEAR MATRIX PROTEIN 22; NUCLEAR PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; LABORATORY DIAGNOSIS; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; TRANSURETHRAL RESECTION; URINALYSIS; URINE CYTOLOGY; UROGENITAL TRACT DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; FALSE POSITIVE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; URINE;

EID: 0035788447     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2001.02355.x     Document Type: Article

References (32)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7-33
2. Catalona WJ. Urothelial tumors of the urinary tract. In Walsh PC, Retik AB, Stamey TA, Vaughan ED eds, Campbell's Urology, 6th edn, Vol II, Chapt 28. Philadelphia: WB Saunders, 1992: 1094-158
3. Abel PD. Prognostic indices in transitional cell carcinoma of the bladder. Br J Urol 1988; 62:103-9
4. Lutzeyer W, Ruebben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 1982; 127: 250-2
5. Deutsche Gesellschaft für Urologie. Leitlinien zur Diagnostik und Therapie des Harnblasenkarzinoms. Urologe [A] 1998; 37: 440-57
6. Murphy WM. Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Path 1990; 21: 886-96
7. Soloway MS, Briggman V, Carpinito GA et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996; 156: 363-7
8. Sarosdy MF, Hudson MA, Ellis WJ et al. Improved detection of recurrent bladder cancer using the Bard BTAstat test. Urology 1997; 50: 349-53
9. Schmetter BS, Habicht KK, Lamm DL et al. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 1997; 158: 801-5
10. Compton DA, Cleveland DW. NuMA is required for the proper completion of meiosis. J Cell Biol 1993; 120: 947-57
11. Keesee SK, Briggman JV, Thill G, Wu YJ. Utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukaryotic Gene Expr 1996; 6: 189-214
12. Kinders R, Jones T, Root R et al. Human bladder tumor antigen is a member of the RCA (regulators of complement activation) gene family. J Urol 1997; 157 (Suppl): 28
13. Chen YT, Hayden CL, Marchand KJ, Makuch RW. Comparison of urine collection methods for evaluating urinary nuclear matrix protein, NMP22, as a tumor marker. J Urol 1997; 158: 1899-901
14. Carpinito GA, Stadler WM, Briggman JV et al. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol 1996; 156: 1280-5
15. Witjes JA, van der Poel HG, van Balken MR, Debruyne FMJ, Schalken JA. Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. Eur Urol 1998; 33: 387-91
16. Wiener H, Mian CH, Haitel A, Pycha A, Schatzl G, Marberger M. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol 1998; 159: 1876-80
17. Ramakumar S, Bhuiyan J, Besse JA et al. Comparison of screening methods in the detection of bladder cancer. J Urol 1999; 161: 388-94
18. Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol 1999; 161: 62-5
19. Leyh H, Marberger M, Conort P et al. Comparison of the BTAstat® Test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol 1999; 35: 52-6
20. Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I. Noninvasive detection of bladder with the BTAstat test. J Urol 1999; 161: 443-6
21. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999; 162: 53-7
22. Zein TA, Milad MF. Urine cytology in bladder tumours. Int Surg 1991; 76: 52-4
23. Heney NM, Ahmed S, Flanagan MJ et al. Superficial bladder cancer: progression and recurrence. J Urol 1983; 130: 1083-6
24. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC-S. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998; 52: 398-402
25. Farrow GM, Utz DC, Rife CC, Greene LF. Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder. Cancer Res 1977; 37: 2794-8
26. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J et al. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 1998; 158: 394-8
27. Sözen S, Biri H, Sinik Z et al. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTAstat test in the diagnosis of transitional cell carcinoma of the bladder. Eur Urol 1999; 36: 225-9
28. Giannopoulos A, Manousakas T, Mitropoulos D et al. Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors. Urology 2000; 55: 871-5
29. Miyanaga N, Akaza H, Ishikawa S et al. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol 1997; 31: 163-8
30. Serretta V, Presti Lo D, Vasile P, Gange E, Esposito E, Menozzi I. Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: Experience on 137 patients. Urology 1998; 52: 793-6
31. Poel HG, Balken van MR, Schamhart DH et al. Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer. Urology 1998; 51: 44-50
32. Leyh H, Mazeman E. Bard BTA test compared with voided cytology in the diagnosis of recurrent bladder cancer. Eur Urol 1997; 32: 425-8